Why the study?
Elderly patients with atrial fibrillation have high risks of stroke and bleeding, motivating an evaluation of the effectiveness and safety of NOACs compared with warfarin in octogenarian patients.
Does the use of non-vitamin K antagonist oral anticoagulants (NOACs) reduce thromboembolic events, major bleeding, and all-cause death in octogenarian patients with non-valvular atrial fibrillation compared to warfarin?
Does the use of non-vitamin K antagonist oral anticoagulants (NOACs) reduce thromboembolic events, major bleeding, and all-cause death in octogenarian patients with non-valvular atrial fibrillation compared to warfarin?
In octogenarian patients with non-valvular atrial fibrillation, NOACs are associated with significantly lower risks of thromboembolic events, major bleeding, and all-cause mortality compared to warfarin.
Answers are grounded in this paper and cite their sources.
Supports NOAC preference in octogenarian NVAF; extends low-certainty observational data but should not yet change practice.
BACKGROUND AND OBJECTIVE: Elderly patients with atrial fibrillation (AF) are known to have a high risk of stroke and bleeding. We investigated the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in octogenarian patients with non-valvular AF compared with warfarin. METHODS: A total of 687 octogenarian patients with AF who were administered NOACs (n = 403) or warfarin (n = 284) for stroke prevention between 2012 and 2016 were included. Thromboembolic (TE) events (stroke or systemic embolism), major bleeding events, and all-cause death were analyzed. RESULTS: The NOACs group (age 83.4±3.2 years, women 52.4%, CHA2DS2-VASc score 5.0±1.8) comprised 141 dabigatran, 158 rivaroxaban, and 104 apixaban users. Most patients from the NOACs group had been prescribed a reduced dose of medication (85.6%). During 14±18 months of follow-up periods, there were 19 TE events and 18 major bleeding events. Patients with NOAC showed a lower risk of TE (1.84 vs. 2.71 per 100 person-years, hazard ration [HR] 0.134, 95% confidence interval [CI] 0.038-0.479, P = 0.002), major bleeding (1.48 vs. 2.72 per 100 person-years, HR 0.110, 95% CI 0.024-0.493, P = 0.001), and all-cause death (2.57 vs. 3.50 per 100 person-years, HR 0.298, 95% CI 0.108-0.824, P = 0.020). CONCLUSION: In octogenarian Asian patients with AF, NOACs might be associated with lower risks of thromboembolic events, major bleeding, and all-cause death than warfarin. Although most patients had received reduced doses, on-label use of NOACs was effective and safe.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: